Reference Research population, setting and study period Study design and sample size Gender, age (mean ± SD) Diagnostic methods Prevalence of lipodystrophy
Santos CL et al. [16]. HIV/AIDS outpatients attending the Aids Hospital of the University of São Paulo Medical School, Brazil.
September to December 2001.
Cross-sectional study n=457 71.4% men.
Mean age 38 years, ranging between 19-74.
Presence of symptoms subjectively reported by patients. 64.3%
Lipohypertrophy=49.2%
Lipoatrophy=37.4%
Mixed=22.3%
Diehl LA et al.[17]. Patients attending the outpatient clinic of infectious diseases of the Clinical Hospital, State University of Londrina, Paraná, Brazil.
June 22 to November 23, 2006.
Cross-sectional study n=180 58.9% men.
Mean age 42.9 ± 10.5 years.
Patient self-report and physician confirmation. 55%
Monnerat BZ et al. [18]. Patients on Antiretroviral therapy recruited from the outpatient clinic at the University Hospital Cassiano Antonio de Morais, Vitória, Espírito Santo, Brazil.
July 2004 to May 2005.
Retrospective cohort study n=96 60.7% men.
Mean age 39.2 years.
Patient self-report and physician confirmation. 59.3%
De Carvalho EH et al. [19]. Patients attending the HIV/AIDS outpatient center, University Hospital Oswaldo Cruz, Recife, Pernambuco, Brazil.
July to December 2007.
Cross-sectional study
n=256
62.1% men.
Mean age 41 ± 9.2 years.
Presence of symptoms subjectively reported by patients. 50.9%
Arruda Júnior EV et al. [20]. Patients attending the outpatient center of Oswaldo Cruz University Hospital, University of Pernambuco and the clinic center of CorreiaPicanço Hospital, state of Pernambuco, Brazil.
June 2007 to December 2008.
Cross-sectional study n=958 61% men.
Mean age 39.6 ± 10 years.
Presence of symptoms subjectively reported by patients. 47% (n=468)
Trinca JR et al. [21]. Patients attending the Hospital de Clínicas of Porto Alegre, Rio Grande do Sul, Brazil.
Unspecified study period.
Cross-sectional study n=410 54.6% men.
Mean age 43 ± 9.4 years.
Presence of clinical signs observed on examination by a physician. 53.4%
Lipohypertrophy=26.5%
Lipoatrophy=38.8%
Mixed=34.7%
Segatto AFM et al. [22]. Patients on antiretroviral therapy enrolled in the Counseling and Testing Center of PresidentePrudente, São Paulo, Brazil. Cross-sectional study n=42 54.8% men.
Age ranged between 31 and 59 years.
Patient self-report and physician confirmation. 42.9%
Ceccato MGB et al. [23]. Medical records of patients on antiretroviral therapy treated at the Reference Center SagradaFamília, Belo Horizonte, Minas Gerais, Brazil.
From 2002 to 2006.
Cross-sectional study n=620 66.5% men.
Mean age 39.2 ± 9.9 years, ranging from 18 to 78 years.
Presence of clinical signs observed on examination by a physician. 32.4%
Gasparotto AS et al.[24]. Referral service for the treatment of HIV in three cities of Rio Grande doSul: Porto Alegre, Pelotas, and Rio Grande, Brazil. Cross-sectional study n=614 55.5% men.
Mean age 42.6 ± 9.5 years.
Presence of clinical signs observed on examination by a physician. 51.1% (n=578)
Lipohypertrophy=25.3%
Lipoatrophy=42.1%
Mixed=32.6%
Signorini DJHP et al.[25]. Patients recruited from the Immunology Laboratory of the University Hospital GrafféeGuinles and the Federal University of Rio de Janeiro, Brazil.
January to May 2005.
Cross-sectional study n=819 54.6% men.
Mean age 41 ± 11 years.
Patient self-report and physician confirmation. 38.5% (n=727)
Lipohypertrophy=12.1%
Lipoatrophy=45.0%
Mixed=42.9%
Signorini DJHP et al. [26]. Patients on initial antiretroviral therapy, attending an outpatient center of a public hospital in Rio de Janeiro, Brazil.
November 2006 to October 2009.
Cross-sectional study n=187 73% men
Mean age 42 years.
Patient self-report and physician confirmation. 45.5%
Ponte CMM [27]. Patients recruited from the HIV/AIDS outpatient center for infectious diseases of São José Hospital, Fortaleza, Ceará, Brazil.
January to June 2010.
Cross-sectional study n=144 64.6% men
Mean age 42.1 ± 7.6 years.
Patient self-report and physician confirmation. 39.4%
Lipohypertrophy=14.6%
Lipoatrophy=28.8%
Mixed=14.4%
Soares LR [28] Secondary Immunodeficiency Outpatient Unit, Department of Dermatology, Hospital de Clínicas, University of São Paulo School of Medicine, Brazil.
June 2007 to December 2008.
Cross-sectional
study
n=227
67% men
Mean age 42.7 ± 8.3, ranging from 20 to 66 years.
Presence of symptoms subjectively reported by patients. 40.5%
Freitas E[29] Patients recruited from a specialized care center of São Vicente, São Paulo, Brazil.
July 2010.
Cross-sectional
study
n=130
43.1% men.
Mean age 42.3 ± 10.5 years.
Patient self-report and physician confirmation. 88.6%
Lipohypertrophy=34.4%
Lipoatrophy=7.5%
Mixed=46.7%
Schuelter-Trevisol, F [30] Patients attending a specialized care center of the State Secretary of Health, the Parthenon Sanatorium Hospital, Porto Alegre, Rio Grande do Sul, Brazil.
From 2006 to 2008.
Cross-sectional study
n=1240
50.6% men.
Mean age 39.1 ± 10.1 years.
Patient self-report and physician confirmation. 74.2%
Lipohypertrophy 46%
Lipoatrophy 53.2%
Table 1: Characteristics of the reviewed studies and estimates of the prevalence of HIV-associated lipodystrophy.
Goto home»